Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study

NCT ID NCT07652736

Recruiting now Knowledge-focused Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes like tumor response. The goal is to understand how the drug performs outside of strict clinical trial settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tislelizumab
What this could lead to
If successful, this study could provide real-world evidence on how well tislelizumab works outside of controlled trials, helping doctors make better treatment decisions for lung cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences and real-world variability. It does not test a new treatment or prove effectiveness definitively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hospital General de Segovia

    RECRUITING

    Segovia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.